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Abstract
Introduction: Despite the progress in the treatment of colorectal cancer, there is still no optimal strategy for
tumours located adjacent to the anal sphincter. This study aims to evaluate oncological and functional results of
surgery for rectal cancer in unfavourable locations in proximity to anal sphincters.
Materials and methods: Patients with rectal cancer, which was either initially infiltrating the anal sphincter or
located in the close proximity of the sphincter, were included in the study. Patients were submitted to extralevator
abdominoperineal resection (APR), intersphincteric resection, or transanal total mesorectal excision (TaTME). Primary
outcomes were perioperative data: operative time, blood loss, complications, length of stay (LOS), and 30-day
mortality. Secondary outcomes were pathological quality of the specimens and functional outcome 6 months after
defunctioning ileostomy closure.
Results: Among patients with cancer adjacent to the anal sphincter, 13 (25%) underwent APR, 14 (27%) patients
were submitted to intersphincteric resection, and 25 (48%) patients were treated with the TaTME approach.
Operative time was 240 (210–270 IQR) for APR, 212.5 (170–260 IQR) for intersphincteric resection, and 270 (240–330
IQR) for TaTME (p = 0.018). Perioperative morbidity was 31% for APR, 36% for intersphincteric resections, and 12%
for the TaTME group (p = 0.181). Complete mesorectal excision was achieved in 92% of specimens in the TaTME
group, 93% in intersphincteric resections, and 78% in the APR group (p = 0.72). Median circumferential resection
margin in APR was 6 mm (4–7 IQR), in intersphincteric resections 7.5 mm (2.5–10 IQR), and in the TaTME group
4 mm (2.8–8 IQR). All patients after intersphincteric resections developed major low anterior resection syndrome
(LARS). Four patients in the TaTME group developed minor LARS, and 21 had major LARS.
Conclusion: Sphincter-saving rectal resections are a feasible alternative to APR with good clinical, pathological, and
oncological outcomes. Intersphincteric resections and TaTME seem to be equal in terms of clinicopathological
results. The functional outcome is yet to be investigated.
Trial registration: The study was retrospectively registered in Thai Clinical Trials Registry (23-07-2018, ID
TCTR20180724001).
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Introduction
Despite the progress in the treatment of colorectal can-
cer, there is still no optimal strategy for tumours located
adjacent to the anal sphincter. Typically, cancers of the
low rectum were submitted to abdominoperineal resec-
tion (APR). Even though APR is believed to give predict-
able oncological results, its acceptance among patients is
very low because of permanent colostomy [1, 2]. Intro-
duction of the intersphincteric resection was hoped to
result in better quality of life (QoL), related to sphincter
preservation without compromising oncological out-
comes [3–6]. Overall, the procedure has failed to attract
the necessary popularity and is performed only in se-
lected centres. The recently developed hybrid approach
to rectal pathology, referred to as TaTME (transanal total
mesorectal excision), allows for an important extension
of indications for sphincter-sparing operations. With
some modifications, it can also be used for ultralow tu-
mours as an interesting alternative to intersphincteric
resections. Despite continuous attempts to decrease the
number of APR procedures [7], its numbers remain
high. Our department for several years now has been
promoting modern strategies aimed at the reduction of
the APR rate. This study aims to evaluate oncological
and functional results of surgery for rectal cancer in un-
favourable locations in proximity to anal sphincters [8].
Material and methods
Setting
A retrospective cohort study, using a prospectively col-
lected database of patients submitted to minimally inva-
sive operations of rectal cancer, was evaluated. We are a
tertiary referral university minimally invasive surgery
unit with the annual volume of 120 laparoscopic colo-
rectal surgeries, including 50 laparoscopic/hybrid rectal
cancer resections. Initially, patients with cancer infiltra-
tion of the anal sphincter were submitted to laparo-
scopic extralevator abdominoperineal resection. In 2013,
minimally invasive intersphincteric resections were in-
troduced. The TaTME procedure was implemented in
2015, and in 2017, we were approved as a COLOR III
participating centre [8]. Since 2016, all procedures re-
quiring internal sphincter removal are performed by
TaTME technique. All procedures were performed by a
surgeon with expert skills in laparoscopic colorectal pro-
cedures. Pathological specimens were assessed by an ex-
perienced pathologist, according to guidelines delivered
by Quirke et al. [9, 10]. The work has been reported in
line with the STROCSS criteria [11].
Patients
Patients with rectal cancer, which was either initially in-
filtrating the anal sphincter or located in the close prox-
imity of the sphincter, were included in the study.
Patients with > T2 tumours and/or positive lymph nodes
were submitted for neoadjuvant chemoradiotherapy in
order to gain downstaging according to current guide-
lines [12]. Before the surgery, MRI restaging was per-
formed in all patients. Those who had persistent
infiltration on the external anal sphincter or levator
muscles were submitted to APR. Other patients were
submitted for either laparoscopic intersphincteric resec-
tion or recently to the modified TaTME procedure. The
operative technique of the abdominal part is described
elsewhere [13]. We used the extralevator approach [14]
for abdominoperineal resection. The technique of inter-
sphincteric rectal resection described by Rullier was used
[15]. In this approach, we used Lone Star Self-Retaining
Retractor® for proper exposition of perianal tissues. The
specimens were extracted transanally, and coloanal anas-
tomosis was performed with single absorbable braided
sutures. The TaTME technique was performed as de-
scribed elsewhere [16]. As a modification, we used the
Karl Storz TEO platform, which enables very low dissec-
tion, starting almost at the anal verge. Whenever pos-
sible, we tried to perform only partial resection of the
internal sphincter or preferably only mucosectomy of
the anal canal. Defunctioning ileostomy was created in
all cases of sphincter-saving procedures. The Enhanced
Recovery After Surgery (ERAS) protocol was used in
perioperative care in all patients [17, 18]. Patients were
followed up every 3 months after surgery. Patients with
stage III and high-risk stage II tumours (poor response
for neoadjuvant treatment, angioinvasion, inadequate
lymphadenectomy, perforation of the tumour) in patho-
logical assessment of the specimen were submitted for
additional adjuvant chemotherapy according to the
ESMO guidelines [19].
Measured outcomes
Primary outcomes were perioperative data: operative time,
blood loss, complications, length of stay (LOS), 30-day
mortality, and 30-day readmission rate. Secondary out-
comes were pathological quality of the specimens, func-
tional outcome 6 months after defunctioning ileostomy
closure, and short- and mid-term oncological outcomes.
Perioperative complications were assessed according to
the Clavien-Dindo classification [20]. Serious complica-
tions were defined as Clavien-Dindo III–V. Pathological
quality parameters were assessed as completeness of
mesorectal excision (intact mesorectal fascia), circumfer-
ential resection margin (CRM), and distal resection mar-
gin (DRM). CRM and DRM > 1 mm were considered as
negative. Tumour regression grade (TRG) was assessed
according to the AJCC criteria [21]. For functional out-
come, we used the Jorge-Wexner scale and LARS (low an-
terior resection syndrome) score [22, 23]. The evaluation
was performed 6 months after defunctioning ileostomy
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reversal in all patients. Patients were evaluated every
3 months post-surgery in order to detect distant metasta-
ses or local recurrence. The follow-up included colonos-
copy and CT scan every year. Local recurrence was
defined as any recurrence in the pelvic region. Distant me-
tastases were defined as any recurrence outside the pelvis.
Statistical analysis and ethical approval
All data were analysed with Statistica version 13.0 PL
(StatSoft Inc., Tulsa, OK, USA). The results are pre-
sented as mean and standard deviation (SD), median,
and interquartile range (IQR). The chi-square test of in-
dependence was used for evaluating categorical variables.
The Shapiro-Wilk test was used to check for normal dis-
tribution of data, and the Student t test was used for
normally distributed quantitative data. For non-normally
distributed quantitative variables, the Mann-Whitney U
test was used. P value < 0.05 was considered statistically
significant.
All procedures were performed in accordance with the
ethical standards of the 1964 Declaration of Helsinki
and its later amendments (Fortaleza 2013). The study
was approved by the Local Ethics Committee (No.
122.6120.198.2016). Every patient signed an informed
consent prior to inclusion in the study.
Results
In the analysed period, 477 colorectal procedures were
performed, including 172 rectal resections and 52 ultra-
low rectal resections. Among patients with cancer adja-
cent to the anal sphincter, 13 (25%) underwent APR,
most of them (9 cases) between 2012 and 2015. Fourteen
(27%) patients were submitted to intersphincteric resec-
tion. Twenty-five (48%) patients were treated with the
modified TaTME approach. The study group design is
presented in Fig. 1. Group characteristics are presented
in Table 1. Tumours were localised at median 2 cm
(range 1–4) from the anal verge for APR patients, 2 cm
(range 1–5) for intersphincteric resections, and 2 cm
(range 1–4) for TaTME patients (p = 0.21). Among pa-
tients treated with APR, 2 had infiltration on the internal
sphincter and were treated before the introduction of
intersphincteric resection, 5 had persistent infiltration
on the external anal sphincter, and 4 had infiltration on
levator muscles. Three patients from the TaTME group
had distant metastases to the liver, which were resectable
and were removed in the second stage. Two patients
underwent laparoscopic metastasectomy, and 1 under-
went laparoscopic right hemihepatectomy.
Operative time was 240 (210–270 IQR) for APR, 212.5
(170–260 IQR) for intersphincteric resection, and 270
(240–330 IQR) for TaTME (p = 0.018). Perioperative out-
comes are presented in Table 2. Perioperative morbidity
was 31% for APR, 36% for intersphincteric resections,
and 12% for the TaTME group (p = 0.181). Serious compli-
cations occurred in 2 patients in the intersphincteric group
and in 2 patients in the TaTME group. Complete mesorec-
tal excision was achieved in 92% of specimens in the
TaTME group, 93% in the intersphincteric resections, and
78% in the APR group (p = 0.72). In other cases, mesorectal
excision was nearly complete (< 5 mm of damage on the
mesorectal fascia). CRM was negative in all cases. Median
CRM in APR was 6 mm (4–7 IQR), in intersphincteric re-
sections 7.5 mm (2.5–10 IQR), and in the TaTME group
4 mm (2.8–8 IQR). We had 2 cases of margin < 1 mm in
TaTME patients and 1 in the APR group.
All patients after intersphincteric resections developed
major LARS with median 34 (32–34 IQR) LARS score
and 12 (11–14 IQR) points in Wexner scale. Four pa-
tients in the TaTME group developed minor LARS, and
21 had major LARS. Median LARS score for the whole
TaTME group was 32 (30–37 IQR) and 11 (8–12 IQR)
in Wexner scale. One patient in the TaTME group had
to have permanent colostomy created due to periopera-
tive complications, and 1 patient in the intersphincteric
group undergone end colostomy creation due to inability
to accept LARS syndrome.
After the 1-year follow-up, 85% of patients with APR
reached disease-free survival (DFS), whereas DFS was
Fig. 1 Study group design (APR—abdominoperineal resection,
IR—intersphincteric resection, TaTME—transanal total
mesorectal excision)
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92% in the intersphincteric group and 96% in the TaTME
group (p = 0.86). One-year overall survival (OS) was
100% in the TaTME group, 100% in the intersphincteric
group, and 93% in the APR group. All patients com-
pleted the 1-year follow-up. The summary of secondary
outcomes is placed in Table 3.
Discussion
In the course of 5 years, we were able to perform
sphincter-saving procedures in 75% of patients. In 25%
of our patients, we performed APR which was inevitable
in those cases. Unfortunately, the majority of patients
suffered from mild to major LARS symptoms, both in
the intersphincteric and TaTME group. We were unable
to document superiority of any of those approaches in
terms of functional results.
APR has been considered a procedure of choice for
very low rectal cancer to achieve a negative resection
margin. Initially, the technique was suboptimal leading
to a high rate of positive margins and perforations in
cases of low tumours frequently adjacent to pelvic floor
muscles. The introduction of extralevator APR improved
the outcomes, but APR remained one of the most stig-
matising procedures in abdominal surgery. This was
until sphincter-saving procedures were introduced. The
shift from extensive operations such as APR was possible
Table 1 Groups’ characteristics
APR Intersphincteric TaTME p value
Males/females, n (%) 8/5 (52%/48%) 12/2 (86%/14%) 19/6 (76%/24%) 0.345
Median age, years (IQR) 60 (55–71) 63 (50–69) 65 (59.5–72.5) 0.462
Median BMI, kg/m2 (IQR) 24.91 (22.31–27.40) 24.82 (24.15–28.73) 24.80 (21.94–26.47) 0.715
ASA class
3 3 (23.08%) 6 (42.86%) 4 (16%) 0.175
2 10 (76.92%) 8 (57.14%) 21 (84%)
T
3 7 (53.85%) 6 (42.86%) 15 (60%) 0.311
2 4 (30.77%) 4 (28.57%) 1 (4%)
1 1 (7.69%) 1 (7.14%) 2 (8%)
0 1 (7.69%) 3 (21.43%) 7 (28%)
N
2 0 1 (7.14%) 5 (20%) 0.381
1 2 (15.38%) 3 (21.43%) 5 (20%
0 11 (84.62%) 10 (71.43%) 15 (60%)
M
1 0 0 3 (12%) 0.179
0 13 (100%) 14 (100%) 22 (88%)
AJCC
4 0 0 4 (16%) 0.414
3 4 (30.77%) 6 (42.86%) 6 (24%)
2 7 (53.85%) 5 (35.71%) 7 (28%)
1 1 (7.69%) 1 (7.14%) 4 (16%)
0 1 (7.69%) 2 (14.29%) 4 (16%)
Neoadjuvant treatment, n (%) 11 (84.62%) 13 (92.86%) 24 (96%) 0.456
Adjuvant treatment, n (%) 6 (46%) 7 (50%) 13(52%) 0.943
Tumour regression grade (TRG)
3 1 (7.69%) 2 (14.29%) 3 (12%) 0.949
2 7 (53.85%) 7 (50%) 14 (56%)
1 4 (30.77%) 3 (21.43%) 4 (16%)
0 1 (7.69%) 2 (14.29%) 4 (16%)
AJCC American Joint Committee on Cancer staging system, ASA American Society of Anesthesiologists class, BMI Body Mass Index, IQR interquartile range, T,N,M
TNM classification
Rubinkiewicz et al. World Journal of Surgical Oncology          (2018) 16:218 Page 4 of 8
thanks to several reasons. The introduction of the min-
imally invasive approach and preoperative neoadjuvant
therapy plays a crucial role in the matter in question.
Laparoscopy and transanal videoendoscopy facilitated
better visualisation of the operative field. The magnified
view allows for more precise identification of tissue
layers, which results in wider resection margins and a
lower rate of local recurrence, which was confirmed in
COLOR II—a large randomised multicentre study—and
also in the meta-analysis of available trials [24–26]. Bet-
ter visualisation may also help to spare pelvic nerves,
whose damage is postulated as a possible cause of faecal
incontinence [27, 28]. Rullier et al. observed that the
treatment of tumours of the anorectal junction through
the combination of preoperative radiotherapy with
sphincter-saving procedures not only may facilitate good
perioperative and functional outcomes, but is also safe
from the oncological point of view [29]. His classical ap-
proach without videoendoscopy was possible thanks to
new devices for perineal step of rectal resection like the
Lone Star retractor. The system provides extraordinary
visualisation of the perianal region, which is much better
than that provided by other retractors or anal retraction
sutures, and this enables the surgeon to focus on the
quality of surgery [30]. With this advances, open and
laparoscopic intersphincteric rectal resection occurred to
be procedures with acceptable clinical outcome [31].
However, the popularity of this approach remains surpris-
ingly low. It is certainly more demanding than APR, and
functional results may look disappointing, but on the
other hand, there is a strong demand among patients for
sphincter preservation. The recently introduced TaTME is
receiving more interest and acceptance among surgeons.
This technique with some modifications may allow for ul-
tralow resection and saving of the sphincter. This is pos-
sible due to the extraordinary exposure of the operating
field, which facilitates more precise surgical techniques.
Neoadjuvant chemoradiotherapy plays an indisputable
role in minimising the aggressiveness of surgical proce-
dures. Those methods result in significant downstaging
of rectal tumours, including T4 cancer [32, 33]. For ultra-
low cancer, neoadjuvant radiotherapy provides an add-
itional benefit in extending the chance for sphincter-saving
procedures [34]. Moreover, complete pathological response
to radiotherapy is associated with a lower local recurrence
rate and improved overall and disease-free survival [35, 36].
In our material, nearly 90% of patients responded to
neoadjuvant chemoradiotherapy; however, only 13%
Table 2 Primary outcomes
APR Intersphincteric TaTME p value
Median operative time, min (IQR) 240 (210–270) 212.5 (170–260) 270 (240–330) 0.018
Median blood loss, ml (IQR) 125 (100–200) 150 (50–200) 150 (100–200) 0.856
Intraoperative adverse events (IAE), n (%) 1 (7.69%) 1 (7.14%) 1 (4%) 0.869
Anastomosis
Circular stapled 0 1 (7.14%) 19 (76%) < 0.001
Hand-sewn coloanal 0 13 (92.86%) 6 (24%)
No anastomosis 13 (100%) 0 0
Sphincter excision (no excision/internal/external) (no. of patients) 0/0/13 1/12/0 20/5/0 < 0.001
Ileostomy, n (%) 0 14 (100%) 25 (100%) < 0.001
Perioperative morbidity 4 (30.77%) 5 (35.71%) 3 (12%) 0.181
Perioperative mortality 0 0 0 n/a
Clavien-Dindo
III 0 2 2 0.094
II 4 3 1
Table 3 Secondary outcomes
APR Intersphincteric TaTME p value
Median CRM, mm (IQR) 6 (4–7) 7.5 (2.5–10) 4 (2.8–8) 0.682
Median DRM, mm (IQR) 28 (12–35) 11 (5–15) 10 (7–15) 0.008
Preoperative Wexner n/a 2 (1–2) 0 (0–2) 0.165
Postoperative Wexner n/a 12 (11–14) 11 (8–12) 0.475
Preoperative LARS n/a 4 (4–6) 5 (0–12) 0.999
Postoperative LARS n/a 34 (32–34) 32 (30–37) 0.397
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had complete pathological response. Nevertheless, the
response to radiotherapy was considered in our series
as an indication for sphincter-saving procedures, as the
“wait and watch” approach still requires full evaluation.
We obtained satisfactory outcomes regarding clinical
features and the quality of pathological specimens using
the intersphincteric resection technique. What is worth
mentioning is that all our patients were treated with
high compliance to the ERAS protocol, which improved
clinical results in abdominal surgery [18, 25, 37, 38]. Our
experiences confirm the results of Laurent et al. which
state that laparoscopic intersphincteric rectal resection
gives acceptable clinical outcomes [31]. Moreover, inter-
sphincteric resection provides good oncological outcomes,
comparable to APR [39–41]. Also, TaTME procedures
yield satisfactory results concerning the quality of patho-
logical specimens with a proper resection margin. When
comparing clinicopathological features in our material, we
failed to demonstrate the superiority of TaTME over inter-
sphincteric resection; however, our subjective opinion
resulted in an almost complete shift to the TaTME pro-
cedure in ultralow tumours. We had 2 patients with a re-
section margin < 1 mm in the TaTME group; thus, some
comment in this field is necessary. We failed to show any
local recurrence during our follow-up in these patients.
This is in line with the observations of others. Fitzgerald
et al. report that in surgical treatment combined with
radiotherapy, the completeness of mesorectal excision and
the negative resection margin (regardless of the distance)
are the most important factors for oncological outcomes
[42]. Moreover, an up-to-date secondary analysis of CAO/
ARO/AIO-04 trial underlines the association between the
quality of mesorectal excision and the 3-year overall and
disease-free survival, which is more important than the
length of the margin [43].
All patients with sphincter-saving procedures, both in
the TaTME and intersphincteric group, developed faecal
incontinence of different severity. However, only 1 pa-
tient from our material who underwent intersphincteric
resection demanded a conversion to a permanent stoma
due to severe faecal incontinence, this being an argu-
ment supporting the wide use of sphincter-saving proce-
dures. Others, despite various degrees of incontinence,
were satisfied with the result and refused colostomy.
The high values of LARS and Wexner scores in both
groups of sphincter-saving procedures in our study may
result from the relatively short (6-month) follow-up
period, as most authors agree that the bowel and pre-
served sphincter require more time for proper adapta-
tion. Nonetheless, the functional outcomes seem to be
promising with high QoL [44]. Kupsch et al. also ob-
tained good results regarding faecal continence; however,
median time of evaluation was 6.5 years after stoma
closure [45]. Chen et al. in their analysis reaching
median 14.6 years of follow-up noted 46% of major
LARS in their population [46]. Nowakowski et al. also re-
port that defunctioning ileostomy, which is a standard pro-
cedure in sphincter-saving procedures, may contribute to
LARS development [47]. Moreover, Celerier observed 22%
of necessity for definitive stoma formation in a 10-year ob-
servation period [48]. Thus, to fully evaluate the outcomes
in our material, we currently follow up our patients to re-
ceive more data and perhaps detect differences in faecal
continence by comparing the TaTME and intersphincteric
group. As the procedure is new, its functional outcomes
are not yet well investigated; however, faecal continence as-
sessment is a part of running RCTs as COLOR III protocol
[8]. According to our knowledge, there are no up-to-date
studies which compare the directly functional outcome in
TaTME and intersphincteric procedures. In our series, the
TaTME patients seem to control defecation better than pa-
tients undergoing intersphincteric resection; however, our
study population is rather low and the follow-up period is
too short to draw definite conclusions. The full evaluation
of the functional outcomes of rectal resections is still a
matter of further consideration.
High-quality randomised control trials comparing
sphincter-saving procedures with abdominoperineal re-
sections are non-existent and probably impossible to
perform. Therefore, the evidence based on a prospective
evaluation of results of sphincter-sparing surgery is cru-
cial to justify the applicability of non-APR procedures in
low rectal cancer.
Our study has some limitations. Firstly, this is a single-
centre study with a limited number of cases. However, the
procedures analysed demand expert skills in colorectal sur-
gery; thus, recruiting other centres is difficult. Also, we were
able to analyse only 1-year overall and disease-free survival.
Although the initial procedures were performed in 2013,
TaTME was introduced in 2015; thus, only few patients
completed a 3-year observational period. Therefore, we
resigned from presenting incomplete data in order to
avoid bias due to different time of follow-up. We also
did not analyse other types of surgery factors that may
contribute to LARS development, for example, the type
of radiotherapy [49].
Conclusion
Sphincter-saving rectal resections are a feasible alterna-
tive to APR with good clinical, pathological, and onco-
logical outcomes. Intersphincteric resections and TaTME
seem to be equal in terms of clinicopathological results.
The functional outcome is yet to be investigated. Efforts
should be taken to limit the indications for APR.
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